Clinical Trials
Lechleiter bets history will repeat for Lilly
January 16, 2012
J.K. WallEli Lilly and Co. CEO John Lechleiter keeps pouring more money into research and development, even as analysts note the payoff
of such spending has dropped off 70 percent in the last decade.
MorePressure rises as Lilly tries squeeze play
January 9, 2012
J.K. WallIndianapolis-based Eli Lilly and Co. is now in the predicament of watching revenue fall as its patents on older products expire,
even as the company needs to spend more money on marketing and research to boost sales of new drugs.
MoreEndocyte stays course despite being battered by investors
December 31, 2011
J.K. WallAfter spending most of 2011 as a Wall Street darling, the year ended ugly for Endocyte Inc. But CEO Ron Ellis thinks the West
Lafayette-based drug developer is in better position than ever.
MorePotential Lilly drug doubles good cholesterol
November 15, 2011
Bloomberg NewsEli Lilly and Co.’s experimental drug doubled levels of good cholesterol in a study, setting up a race with Merck &
Co. and Roche Holding AG to develop a new class of medicines to lower heart risk.
MoreDrug shortages hit Lilly, Endocyte
November 7, 2011
J.K. WallThe nation’s shortage of certain drugs is threatening to affect research trials being conducted by Eli Lilly and Co.
and Endocyte Inc.
MoreLilly fights view that fate hinges on Alzheimer's drug
October 29, 2011
Greg AndrewsAnalysts have eyes on trial data for drug that could be a game-changer for the company.
MoreQ&A
October 17, 2011
J.K. WallSherry Keramidas, who earned her doctorate in neuroscience and physiological psychology from Purdue University,
is executive director of the Maryland-based Regulatory Affairs Professionals Society, which is holding its annual conference
Oct. 22-26 at the Indiana Convention Center.
MoreLilly: Alzheimer's patients on failed drug didn’t improve
July 19, 2011
Bloomberg NewsEli Lilly and Co. said patients with Alzheimer’s disease whose conditions worsened upon taking the experimental drug
semagacestat didn’t improve after dosing was halted.
MoreFDA says potential diabetes drug may cause cancer
July 18, 2011
Bloomberg NewsDapagliflozin would be the first in a new class of diabetes treatments called SGLT2-inhibitors that work by letting patients
excrete excess blood sugar in their urine. Indianapolis-based Eli Lilly and Co. is among several companies pursuing similar
drugs.
MoreTiming good for 2-in-1 biotech drugs
July 5, 2011
J.K. WallEli Lilly and Co.’s foray into combination drugs is well-timed because the company could take advantage of some the
world’s most successful biotech medicines, which are about to see their patents expire.
MoreLilly plans 10 drugs in final-stage trials by year's end
June 30, 2011
Bloomberg NewsLilly has 33 drugs in the second and third stages of clinical trials, including medicines for cancer, diabetes and Alzheimer’s
disease, up from seven in 2005, the Indianapolis-based company said Thursday.
MoreLilly, partner find no Bydureon effect on heart rhythm
June 27, 2011
Bloomberg NewsEli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. said an analysis of a 148-patient trial found no evidence
that their experimental Bydureon diabetes drug causes prolonged heart rhythms.
MoreFDA OKs new diabetes pill from Lilly, Boehringer
May 2, 2011
IBJ Staff and Associated PressThe Food and Drug Administration says it has approved a new diabetes pill from Boehringer Ingelheim and Eli Lilly for patients
who can't control their blood sugar with older medicines.
MoreChina making big gains in drug R&D jobs state covets
April 9, 2011
Greg AndrewsThe total annual cost for one researcher at Lilly might run $300,000 to $350,000 a year. The figure at Crown Bioscience is
one-third of that, said a company executive.
MoreEli Lilly neuroscience chief resigns
February 25, 2011
J.K. WallDavid Bredt, vice president of neuroscience research, has resigned “to pursue other opportunities,” according
to Lilly spokeswoman Judy Kay Moore. Bredt had overseen Lilly’s development of various drugs, including molecules in
late-stage human testing to treat Alzheimer’s and depression.
MoreLilly, Bristol-Myers halt enrollment in lung-cancer trial
February 2, 2011
J.K. WallEli Lilly and Co. and Bristol-Myers Squibb Co. stopped enrolling new patients in a clinical trial of an experimental lung
cancer drug over concerns about patients developing blood clots.
MoreLilly imaging drug isn't ready for approval, FDA says
January 18, 2011
Eli Lilly and Co.’s experimental drug to help identify plaque in the brain tied to Alzheimer's disease isn't ready for approval,
according to U.S. regulators.
MoreLilly partner moves up timetable for diabetes drug
January 11, 2011
Bloomberg NewsAmylin Pharmaceuticals Inc., rebuffed twice in its bid for U.S. approval of a weekly diabetes drug, will meet its timetable
and submit a heart-safety study to regulators by the end of 2011, its CEO said.
MoreLilly, other big drugmakers shut out by FDA in 2010
January 3, 2011
IBJ Staff and Bloomberg NewsRegulators cleared 21 medicines, the fewest since 2007, for sale last year. It was the first time in a decade that Pfizer
Inc., the world's largest drugmaker, as well as Lilly, Merck & Co. and Bristol-Myers Squibb Co. were shut out at the same
time, according to agency records.
MoreIndiana Seed Fund makes 11th investment
December 23, 2010
IBJ StaffA $250,000 investment in Aarden Pharmaceuticals will go toward advancing tuberculosis therapy through the pre-clinical development
stage.
MoreLilly suspends late-stage trial for melanoma drug
December 13, 2010
Bloomberg NewsEli Lilly and Co. suspended a late-stage clinical trial of a medicine for skin-cancer patients after 12 patients in the study
died.
MoreLilly, Acrux receive FDA approval for Axiron
November 24, 2010
IBJ Staff and Bloomberg NewsThe companies believe the underarm testosterone solution has the potential to realize sales of more than $1 billion a year
in the United States.
MoreLilly scores series of small victories
November 17, 2010
J.K. WallThe Indianapolis-based drugmaker finally won FDA approval for its antidepressant Cymbalta to treat chronic pain and fended
off a patent challenge to rising-star cancer drug Alimta, but got a ratings downgrade on its debt.
MoreStudy: Arthritis drug co-developed by Lilly shows promise
November 12, 2010
IBJ Staff and Bloomberg NewsLilly paid $90 million in 2009 to acquire the global rights to the treatment in a bid to beef up its pipeline of medications
for autoimmune diseases.
MoreEli Lilly will have to beat odds to meet drug-rollout goals
October 30, 2010
J.K. WallEli Lilly and Co. executives have said repeatedly that the company’s bulging pipeline will produce two new drugs per
year, beginning in 2013. But only three times in the past six decades has Lilly been able to launch two or more new drugs
in back-to-back years.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
IBJ Featured Advertisers
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
Members must realize if you stop paying your dues you will lose. Why else would your employer honor the rtw bill. Before you take this step think about what you may be giving up in the long run. Very little of your dues money goes to any dem candidate. YOu will never know how much your republican employer gives his party with money he could be paying the employee. Who will step up and demand better wages or benefits if you have no representation. Union is the way for a better life. Our carpenter union offers a 4 year apprenticeship and 2 year degree from Ivy Tech all paid for with union dues . This is a great opportunity for kids who cant afford schooling after high school. The same opportunity is there for any person,any age, either sex to provide a better living for their family. Pension, anuity, health insurance all for your dues. How is this a bad choice.
The FDIC is funded by assessments paid by banks, not taxpayers. That is not to say that bank customers don't ultimately pay the cost because, in the end, banks don't survive if they don't make profits.
SCB Bank's failure is expected to cost the government $33.9 million,dont you mean middle class another bailout our government has no money
Diogenes, the company did not call "pro-life" statements inflammatory. The IBJ article used the words "pro life."
All, the company did, is what it should do which is apologize profusely for offending people with a program that offered statements that support an infamous apartheid proponent, Dr. Verwoerd, suggest that sometimes rape is justified, and quote Biblical text to people, not looking for it.
If this is what you think is "insanity" then more companies need to behave insanely.
I totally disagree with $45mil being given to the state Attorney General's office. That money is a waste. All of the money should go to help the homeowners & the people who were foreclosed on. Why such a big percentage to state govt? They'll get to start another agency staffed with people who have new-found power & don't care about the people they serve. As soon as the program was announced, I knew the states would end up with a huge chunk of the money for themselves that would just be squandered. Or maybe Mitch Daniels will just happen to "find" another big chunk of money that was "posted in the wrong section of the state's books."